This document summarizes one and two compartment open models for extravascular drug administration. It describes how compartment models are used to simplify drug distribution and elimination processes in the body. A one compartment open model is presented, showing drug absorption from extravascular administration followed by distribution and elimination from the body compartment. Equations are provided to describe drug behavior under zero-order and first-order absorption. Methods for estimating the absorption rate constant like residuals and Wagner-Nelson are also summarized. Finally, a two compartment open model is briefly introduced.
The document discusses different types of validation processes that are important for pharmaceutical manufacturing. It describes process validation, cleaning validation, equipment validation, and validation of analytical methods. Process validation ensures a process is capable of consistently producing quality products and includes prospective, concurrent, retrospective, and revalidation. Cleaning validation aims to minimize cross-contamination. Equipment validation proves equipment works correctly. Validation of analytical methods establishes that test method performance meets requirements for intended use. Government regulations require validation to ensure drug quality and safety.
WHO GUIDELINES FOR TECH.TRANSFER SIDHANTA SAHU.GvDurgamani
This document provides information about technology transfer in the pharmaceutical industry. It defines technology transfer as the logical procedure that controls the transfer of any process along with documentation and expertise between development and manufacturing sites. The WHO guidelines for technology transfer provide a flexible framework to guide the transfer process with a focus on quality. The scope of the WHO guidelines includes guidance for transferring manufacturing processes of APIs, packaging, and all dosage forms. Reasons for technology transfer include a lack of manufacturing capacity, resources, or marketing capabilities.
This document discusses pilot plant design, operation, and scale up considerations for pharmaceutical manufacturing processes. It provides an overview of the need for pilot plants and scale up to transfer processes from the laboratory to production scale. Key sections include descriptions of pilot plant attributes, operational aspects like validation and training, scale up principles of similarity, and development milestones from formulation through clinical and commercial production. Process parameters that should be evaluated at various stages like mixing, drying, milling and compression are also outlined.
Technology Transfer Related Documents.pptxAfroj Shaikh
SlideShare Description: Technology Transfer Related Documents
Welcome to SlideShare's collection of technology transfer related documents in the field of pharmacy. This presentation focuses on the essential documentation needed for successful technology transfer in pharmaceutical manufacturing, emphasizing its role in ensuring quality, safety, and regulatory compliance.
Technology transfer plays a crucial role in the dynamic and ever-evolving field of pharmacy. It facilitates the smooth transfer of knowledge, processes, and technologies from research and development to commercial production. To ensure a seamless transition, a well-defined set of documents is required to capture critical information, procedures, and controls.
This SlideShare presentation explores the key documents involved in technology transfer within the pharmaceutical industry. The technology transfer protocol is discussed first, highlighting its purpose, contents, and significance. Acting as a roadmap, this protocol outlines the transfer scope, stakeholder responsibilities, timelines, and acceptance criteria, promoting effective communication and collaboration between the sending and receiving units.
The importance of comprehensive process descriptions is also emphasized. These documents detail the manufacturing process, equipment specifications, critical parameters, and in-process controls. They serve as a guide for the receiving unit to replicate the process accurately, ensuring consistent product quality and performance.
Validation and qualification protocols are addressed as well, highlighting their role in verifying that equipment, processes, and systems are suitable for their intended use. These protocols are crucial for meeting regulatory requirements and mitigating risks associated with the transfer.
Analytical method transfer documents are discussed next, encompassing the procedures for transferring and validating analytical methods used to assess the quality attributes of pharmaceutical products. Robust analytical methods are essential to ensure accurate and reliable test results throughout the product lifecycle.
The presentation also covers documentation related to training, risk assessments, change control, and deviation management. These documents help establish a robust quality management system, ensuring adherence to regulatory standards and facilitating continuous improvement.
Whether you're involved in technology transfer, quality assurance, or regulatory affairs, this SlideShare is a valuable resource for understanding the essential documents involved in successful technology transfer within the pharmaceutical industry. By leveraging these documents effectively, you can ensure a seamless transfer process, maintain product quality, and uphold patient safety.
Explore our SlideShare and gain the knowledge necessary to navigate the intricacies of technology transfer in pharmacy. Stay updated with the latest best practices and regulatory guidelines.
SUPAC Guidelines for Pilot plant Scale up vibhutidubey1
The document discusses post-approval changes (SUPAC) to drug manufacturing processes and guidelines for evaluating such changes. It defines four levels of changes - site changes, batch size changes, manufacturing changes, and composition changes. For each level of change, it provides recommendations on chemistry and bioequivalence testing to evaluate the impact on drug quality and performance. The guidelines aim to ensure quality is maintained when changes are made following drug approval.
The document discusses the level of detail that should be provided about active pharmaceutical ingredients (APIs), excipients, finished products, and packaging materials when transferring technology from a source unit (SU) to a recipient unit (RU). For APIs, the SU should provide information such as the manufacturer, synthesis process, impurities, and stability studies. For excipients, the SU should detail the manufacturer, category, properties like solubility, and specifications for different dosage forms. The finished product specifications, storage conditions, and analytical test procedures should also be transferred. Finally, the SU should inform the RU about the suitable packaging, labeling, and ensure the packaging will not degrade the product.
This document summarizes one and two compartment open models for extravascular drug administration. It describes how compartment models are used to simplify drug distribution and elimination processes in the body. A one compartment open model is presented, showing drug absorption from extravascular administration followed by distribution and elimination from the body compartment. Equations are provided to describe drug behavior under zero-order and first-order absorption. Methods for estimating the absorption rate constant like residuals and Wagner-Nelson are also summarized. Finally, a two compartment open model is briefly introduced.
The document discusses different types of validation processes that are important for pharmaceutical manufacturing. It describes process validation, cleaning validation, equipment validation, and validation of analytical methods. Process validation ensures a process is capable of consistently producing quality products and includes prospective, concurrent, retrospective, and revalidation. Cleaning validation aims to minimize cross-contamination. Equipment validation proves equipment works correctly. Validation of analytical methods establishes that test method performance meets requirements for intended use. Government regulations require validation to ensure drug quality and safety.
WHO GUIDELINES FOR TECH.TRANSFER SIDHANTA SAHU.GvDurgamani
This document provides information about technology transfer in the pharmaceutical industry. It defines technology transfer as the logical procedure that controls the transfer of any process along with documentation and expertise between development and manufacturing sites. The WHO guidelines for technology transfer provide a flexible framework to guide the transfer process with a focus on quality. The scope of the WHO guidelines includes guidance for transferring manufacturing processes of APIs, packaging, and all dosage forms. Reasons for technology transfer include a lack of manufacturing capacity, resources, or marketing capabilities.
This document discusses pilot plant design, operation, and scale up considerations for pharmaceutical manufacturing processes. It provides an overview of the need for pilot plants and scale up to transfer processes from the laboratory to production scale. Key sections include descriptions of pilot plant attributes, operational aspects like validation and training, scale up principles of similarity, and development milestones from formulation through clinical and commercial production. Process parameters that should be evaluated at various stages like mixing, drying, milling and compression are also outlined.
Technology Transfer Related Documents.pptxAfroj Shaikh
SlideShare Description: Technology Transfer Related Documents
Welcome to SlideShare's collection of technology transfer related documents in the field of pharmacy. This presentation focuses on the essential documentation needed for successful technology transfer in pharmaceutical manufacturing, emphasizing its role in ensuring quality, safety, and regulatory compliance.
Technology transfer plays a crucial role in the dynamic and ever-evolving field of pharmacy. It facilitates the smooth transfer of knowledge, processes, and technologies from research and development to commercial production. To ensure a seamless transition, a well-defined set of documents is required to capture critical information, procedures, and controls.
This SlideShare presentation explores the key documents involved in technology transfer within the pharmaceutical industry. The technology transfer protocol is discussed first, highlighting its purpose, contents, and significance. Acting as a roadmap, this protocol outlines the transfer scope, stakeholder responsibilities, timelines, and acceptance criteria, promoting effective communication and collaboration between the sending and receiving units.
The importance of comprehensive process descriptions is also emphasized. These documents detail the manufacturing process, equipment specifications, critical parameters, and in-process controls. They serve as a guide for the receiving unit to replicate the process accurately, ensuring consistent product quality and performance.
Validation and qualification protocols are addressed as well, highlighting their role in verifying that equipment, processes, and systems are suitable for their intended use. These protocols are crucial for meeting regulatory requirements and mitigating risks associated with the transfer.
Analytical method transfer documents are discussed next, encompassing the procedures for transferring and validating analytical methods used to assess the quality attributes of pharmaceutical products. Robust analytical methods are essential to ensure accurate and reliable test results throughout the product lifecycle.
The presentation also covers documentation related to training, risk assessments, change control, and deviation management. These documents help establish a robust quality management system, ensuring adherence to regulatory standards and facilitating continuous improvement.
Whether you're involved in technology transfer, quality assurance, or regulatory affairs, this SlideShare is a valuable resource for understanding the essential documents involved in successful technology transfer within the pharmaceutical industry. By leveraging these documents effectively, you can ensure a seamless transfer process, maintain product quality, and uphold patient safety.
Explore our SlideShare and gain the knowledge necessary to navigate the intricacies of technology transfer in pharmacy. Stay updated with the latest best practices and regulatory guidelines.
SUPAC Guidelines for Pilot plant Scale up vibhutidubey1
The document discusses post-approval changes (SUPAC) to drug manufacturing processes and guidelines for evaluating such changes. It defines four levels of changes - site changes, batch size changes, manufacturing changes, and composition changes. For each level of change, it provides recommendations on chemistry and bioequivalence testing to evaluate the impact on drug quality and performance. The guidelines aim to ensure quality is maintained when changes are made following drug approval.
The document discusses the level of detail that should be provided about active pharmaceutical ingredients (APIs), excipients, finished products, and packaging materials when transferring technology from a source unit (SU) to a recipient unit (RU). For APIs, the SU should provide information such as the manufacturer, synthesis process, impurities, and stability studies. For excipients, the SU should detail the manufacturer, category, properties like solubility, and specifications for different dosage forms. The finished product specifications, storage conditions, and analytical test procedures should also be transferred. Finally, the SU should inform the RU about the suitable packaging, labeling, and ensure the packaging will not degrade the product.
The document discusses pilot plant scale-up techniques. It defines a pilot plant as transforming a lab scale formula into a viable manufacturing process. The objectives of a pilot plant include testing the process before committing funds to full production and examining the formula's ability to withstand scaling. Key steps in scale-up involve defining product economics, conducting lab and planning studies, evaluating rate-controlling steps, designing and constructing a pilot plant, and evaluating results. General considerations for scale-up include personnel requirements, equipment selection, production rates, and process evaluation.
Document Maintenance in Pharmaceutical IndustryNAKUL DHORE
Document Maintenance in Pharmaceutical Industry.
By_ NAKUL DHORE
❖ Introduction
❖ Batch Formula Record
❖ Master Formula Record
❖ SOPs
❖ Quality Audit
❖ Quality Review & Quality Documentation
❖ Reports & Documents
❖ Distribution Records
❖ MCQs
Quality Assurance
As per B.PHARM 3rd Year Semester-6
(PCI Syllabus New)
Microencapsulation methods can be categorized into physical or physico-chemical methods. Physical methods include pan coating, air suspension, spray drying, and centrifugal extrusion which use mechanical means to apply encapsulating materials onto core particles. Physico-chemical methods use phase separation and polymerization reactions, such as coacervation, supercritical fluid extraction, and sol-gel encapsulation, to form encapsulating shells around active ingredients.
Pilot Plant:-
“Defined as a part of pharmaceutical industry where a lab scale formula is transformed into viable product by the development of liable practical procedure for manufacture”.
Scale-up:-
“The art of designing of prototype using the data obtained from the pilot plant model”
A pilot plant allows investigation of a product and process on an intermediate scale before committing to full-scale production. It permits examination of formulae to determine ability to withstand scale-up and process modification. Pilot plant studies help identify critical process features, provide production guidelines and controls, and avoid scale-up problems. The document outlines steps for conducting pilot plant studies including laboratory work, preliminary larger studies, and defining rate-controlling steps before designing and constructing a pilot plant.
Pilot plant scaleup techniques used in pharmaceutical manufacturingSunil Boreddy Rx
The document discusses pilot plant scale-up techniques. It defines a pilot plant as transforming a lab scale formula into a viable product through developing a reliable manufacturing process. The objectives of pilot plant studies are to examine a formula's ability to withstand scale-up, identify critical process aspects, and provide manufacturing guidelines to avoid problems. Key considerations for pilot plants include personnel requirements, equipment selection, production rates, process evaluation, and product stability testing.
The document discusses Supplemental Abbreviated Changes to an Approved Application (SUPAC) guidelines for post-approval changes to pharmaceutical drug products. It defines three levels of changes - minor, moderate, and major - and provides recommendations for documentation and necessary filings based on the level of change for components/composition, manufacturing equipment, processes, batch size, and site changes. Minor changes may only require annual reporting, while major changes involving new excipients, processes, or sites would necessitate prior approval supplements and additional testing.
This document discusses targeted drug delivery systems. It begins with an introduction defining targeted drug delivery as selectively delivering medication only to its site of action and not other organs. It then discusses various strategies for targeted delivery including passive targeting using physiological properties and active targeting using surface modifications like antibodies. Several types of targeted delivery systems are mentioned, such as liposomes, nanotubes, nanoshells and others, along with their applications. The advantages of targeted delivery in reducing toxicity and dose are also outlined.
Technology transfer involves the systematic transfer of a technology from research and development to production. It requires a technology transfer team consisting of representatives from R&D, quality assurance, production, engineering and quality control. The technology transfer process involves multiple stages, beginning with development of the technology in R&D. R&D then provides a technology transfer dossier to production with documentation including the master formula, manufacturing instructions, specifications and analytical methods. Successful technology transfer depends on open communication between both the sending and receiving units.
The document summarizes the key aspects of a Master Formula Record (MFR), including:
- The MFR is prepared by the R&D team and contains all information about the manufacturing process for a pharmaceutical product, including starting materials, packaging details, production steps, and quality checks.
- It serves as the reference standard for individual batch manufacturing records.
- The MFR includes detailed information like product name, active ingredients, batch size, equipment used, production steps, packaging process, theoretical and actual yields, and storage conditions.
- Preparing the MFR involves production and R&D teams and follows a standardized format and approval process.
Microencapsulation is a process where core materials are surrounded by a coating to form microparticles or microcapsules between 3-800 μm in size. It can be used to increase bioavailability, alter drug release, improve compliance, enable targeted delivery, and mask tastes. Various techniques like coacervation, spray drying, solvent evaporation, and pan coating can be used. Polymers are common coating materials and microencapsulation can protect core materials, control reactivity, and convert liquids to solids. The microparticles are evaluated based on morphology, drug content, particle size, and dissolution studies.
This document discusses general considerations for pilot plant scale up techniques. It outlines 12 key areas that should be considered when scaling up a formulation from the laboratory to a pilot plant scale, including reporting responsibilities, personnel requirements, space requirements, reviewing the formula, raw materials, processing equipment, production rates, process evaluation, manufacturing procedures, product stability and uniformity, GMP compliance, and transferring analytical methods to quality assurance. The goal is to produce a formulation on an intermediate batch scale that represents the procedures used for commercial manufacturing.
Ndds 6 Implantable Drug Delivery Systemshashankc10
Implants are solid masses containing a purified drug that provide controlled release of the drug over a long period of time after implantation. They can be biodegradable or non-biodegradable. Implants offer benefits like continuous drug delivery, avoidance of peak concentrations, enhanced efficacy and minimized side effects. However, they can cause reactions with the host, require surgery for large implants, and have issues with release rates. The document discusses various types of implants based on their drug release mechanisms and provides examples of implants used to treat conditions like cancer, osteoporosis, and for contraception.
Phytosomes are advanced herbal formulations containing bioactive plant constituents bound to phospholipids. This improves absorption and bioavailability compared to conventional herbal extracts. Phytosomes are prepared by reacting phytoconstituents like flavonoids with phosphatidylcholine in solvent to form a complex. They have advantages like reduced dose requirements and synergistic effects when combined with hepatoprotective substances. Common phytosome applications include milk thistle for liver protection, grape seed for antioxidants, green tea for various health benefits, and curcumin for its anti-inflammatory properties.
This document discusses ICH guidelines and regulatory requirements for pharmaceutical products in various countries and regions. It provides an overview of the ICH structure and goals of harmonization. The key guidelines cover quality, safety, efficacy, and multidisciplinary topics. Regulatory requirements for the EU, MHRA, TGA, and rest of world are then outlined, focusing on their roles in ensuring safety, efficacy and quality of medicines.
This document provides an overview of equipments and raw materials used in pharmaceutical manufacturing. It discusses the selection, purchase specifications, maintenance, and storage of both equipments and raw materials. Key points covered include cleaning and calibration of equipments, purchasing raw materials from approved vendors against specifications, and storing materials under proper conditions to prevent degradation.
This document discusses pilot plant scale up techniques. It defines a pilot plant as transforming a lab scale formula into a viable product through practical manufacturing procedures. The objectives of pilot plant studies are to examine a formula's ability to withstand scale changes and identify critical process features before committing to full production. Key steps include defining rate-controlling steps, designing and constructing a pilot plant, evaluating results, and making corrections before full-scale development. General considerations are also outlined, such as personnel requirements, equipment, production rates, and process evaluation.
This document discusses pilot plant scale-up techniques for pharmaceutical manufacturing. It defines a pilot plant and scale-up process. The key steps in scale-up involve conducting laboratory and smaller pilot studies, designing and constructing a pilot plant, evaluating results to make corrections, and deciding whether to proceed to full-scale production. General considerations for a pilot plant include personnel requirements, equipment, production rates, process evaluation, and ensuring product stability and uniformity. GMP must also be followed in areas like process validation and documentation.
The document discusses pilot plant scale-up techniques. It defines a pilot plant as transforming a lab scale formula into a viable manufacturing process. The objectives of a pilot plant include testing the process before committing funds to full production and examining the formula's ability to withstand scaling. Key steps in scale-up involve defining product economics, conducting lab and planning studies, evaluating rate-controlling steps, designing and constructing a pilot plant, and evaluating results. General considerations for scale-up include personnel requirements, equipment selection, production rates, and process evaluation.
Document Maintenance in Pharmaceutical IndustryNAKUL DHORE
Document Maintenance in Pharmaceutical Industry.
By_ NAKUL DHORE
❖ Introduction
❖ Batch Formula Record
❖ Master Formula Record
❖ SOPs
❖ Quality Audit
❖ Quality Review & Quality Documentation
❖ Reports & Documents
❖ Distribution Records
❖ MCQs
Quality Assurance
As per B.PHARM 3rd Year Semester-6
(PCI Syllabus New)
Microencapsulation methods can be categorized into physical or physico-chemical methods. Physical methods include pan coating, air suspension, spray drying, and centrifugal extrusion which use mechanical means to apply encapsulating materials onto core particles. Physico-chemical methods use phase separation and polymerization reactions, such as coacervation, supercritical fluid extraction, and sol-gel encapsulation, to form encapsulating shells around active ingredients.
Pilot Plant:-
“Defined as a part of pharmaceutical industry where a lab scale formula is transformed into viable product by the development of liable practical procedure for manufacture”.
Scale-up:-
“The art of designing of prototype using the data obtained from the pilot plant model”
A pilot plant allows investigation of a product and process on an intermediate scale before committing to full-scale production. It permits examination of formulae to determine ability to withstand scale-up and process modification. Pilot plant studies help identify critical process features, provide production guidelines and controls, and avoid scale-up problems. The document outlines steps for conducting pilot plant studies including laboratory work, preliminary larger studies, and defining rate-controlling steps before designing and constructing a pilot plant.
Pilot plant scaleup techniques used in pharmaceutical manufacturingSunil Boreddy Rx
The document discusses pilot plant scale-up techniques. It defines a pilot plant as transforming a lab scale formula into a viable product through developing a reliable manufacturing process. The objectives of pilot plant studies are to examine a formula's ability to withstand scale-up, identify critical process aspects, and provide manufacturing guidelines to avoid problems. Key considerations for pilot plants include personnel requirements, equipment selection, production rates, process evaluation, and product stability testing.
The document discusses Supplemental Abbreviated Changes to an Approved Application (SUPAC) guidelines for post-approval changes to pharmaceutical drug products. It defines three levels of changes - minor, moderate, and major - and provides recommendations for documentation and necessary filings based on the level of change for components/composition, manufacturing equipment, processes, batch size, and site changes. Minor changes may only require annual reporting, while major changes involving new excipients, processes, or sites would necessitate prior approval supplements and additional testing.
This document discusses targeted drug delivery systems. It begins with an introduction defining targeted drug delivery as selectively delivering medication only to its site of action and not other organs. It then discusses various strategies for targeted delivery including passive targeting using physiological properties and active targeting using surface modifications like antibodies. Several types of targeted delivery systems are mentioned, such as liposomes, nanotubes, nanoshells and others, along with their applications. The advantages of targeted delivery in reducing toxicity and dose are also outlined.
Technology transfer involves the systematic transfer of a technology from research and development to production. It requires a technology transfer team consisting of representatives from R&D, quality assurance, production, engineering and quality control. The technology transfer process involves multiple stages, beginning with development of the technology in R&D. R&D then provides a technology transfer dossier to production with documentation including the master formula, manufacturing instructions, specifications and analytical methods. Successful technology transfer depends on open communication between both the sending and receiving units.
The document summarizes the key aspects of a Master Formula Record (MFR), including:
- The MFR is prepared by the R&D team and contains all information about the manufacturing process for a pharmaceutical product, including starting materials, packaging details, production steps, and quality checks.
- It serves as the reference standard for individual batch manufacturing records.
- The MFR includes detailed information like product name, active ingredients, batch size, equipment used, production steps, packaging process, theoretical and actual yields, and storage conditions.
- Preparing the MFR involves production and R&D teams and follows a standardized format and approval process.
Microencapsulation is a process where core materials are surrounded by a coating to form microparticles or microcapsules between 3-800 μm in size. It can be used to increase bioavailability, alter drug release, improve compliance, enable targeted delivery, and mask tastes. Various techniques like coacervation, spray drying, solvent evaporation, and pan coating can be used. Polymers are common coating materials and microencapsulation can protect core materials, control reactivity, and convert liquids to solids. The microparticles are evaluated based on morphology, drug content, particle size, and dissolution studies.
This document discusses general considerations for pilot plant scale up techniques. It outlines 12 key areas that should be considered when scaling up a formulation from the laboratory to a pilot plant scale, including reporting responsibilities, personnel requirements, space requirements, reviewing the formula, raw materials, processing equipment, production rates, process evaluation, manufacturing procedures, product stability and uniformity, GMP compliance, and transferring analytical methods to quality assurance. The goal is to produce a formulation on an intermediate batch scale that represents the procedures used for commercial manufacturing.
Ndds 6 Implantable Drug Delivery Systemshashankc10
Implants are solid masses containing a purified drug that provide controlled release of the drug over a long period of time after implantation. They can be biodegradable or non-biodegradable. Implants offer benefits like continuous drug delivery, avoidance of peak concentrations, enhanced efficacy and minimized side effects. However, they can cause reactions with the host, require surgery for large implants, and have issues with release rates. The document discusses various types of implants based on their drug release mechanisms and provides examples of implants used to treat conditions like cancer, osteoporosis, and for contraception.
Phytosomes are advanced herbal formulations containing bioactive plant constituents bound to phospholipids. This improves absorption and bioavailability compared to conventional herbal extracts. Phytosomes are prepared by reacting phytoconstituents like flavonoids with phosphatidylcholine in solvent to form a complex. They have advantages like reduced dose requirements and synergistic effects when combined with hepatoprotective substances. Common phytosome applications include milk thistle for liver protection, grape seed for antioxidants, green tea for various health benefits, and curcumin for its anti-inflammatory properties.
This document discusses ICH guidelines and regulatory requirements for pharmaceutical products in various countries and regions. It provides an overview of the ICH structure and goals of harmonization. The key guidelines cover quality, safety, efficacy, and multidisciplinary topics. Regulatory requirements for the EU, MHRA, TGA, and rest of world are then outlined, focusing on their roles in ensuring safety, efficacy and quality of medicines.
This document provides an overview of equipments and raw materials used in pharmaceutical manufacturing. It discusses the selection, purchase specifications, maintenance, and storage of both equipments and raw materials. Key points covered include cleaning and calibration of equipments, purchasing raw materials from approved vendors against specifications, and storing materials under proper conditions to prevent degradation.
This document discusses pilot plant scale up techniques. It defines a pilot plant as transforming a lab scale formula into a viable product through practical manufacturing procedures. The objectives of pilot plant studies are to examine a formula's ability to withstand scale changes and identify critical process features before committing to full production. Key steps include defining rate-controlling steps, designing and constructing a pilot plant, evaluating results, and making corrections before full-scale development. General considerations are also outlined, such as personnel requirements, equipment, production rates, and process evaluation.
This document discusses pilot plant scale-up techniques for pharmaceutical manufacturing. It defines a pilot plant and scale-up process. The key steps in scale-up involve conducting laboratory and smaller pilot studies, designing and constructing a pilot plant, evaluating results to make corrections, and deciding whether to proceed to full-scale production. General considerations for a pilot plant include personnel requirements, equipment, production rates, process evaluation, and ensuring product stability and uniformity. GMP must also be followed in areas like process validation and documentation.
This document discusses pilot plant scale-up techniques for pharmaceutical manufacturing. It defines a pilot plant and scale-up process. The key steps in scale-up involve conducting laboratory and smaller pilot studies, designing and constructing a pilot plant, evaluating results to make corrections, and deciding whether to proceed to full-scale production. General considerations for a pilot plant include personnel requirements, equipment, production rates, process evaluation, and ensuring product stability and uniformity. GMP must also be followed in areas like process validation and documentation.
This document discusses pilot plant scale-up techniques for pharmaceutical manufacturing. It defines a pilot plant and scale-up process. The key steps in scale-up involve conducting laboratory and smaller pilot studies, designing and constructing a pilot plant, evaluating results to make corrections, and deciding whether to proceed to full-scale production. General considerations for a pilot plant include personnel requirements, equipment, production rates, process evaluation, and ensuring product stability and uniformity. GMP must also be followed in areas like process validation and documentation.
The uploaded Power point presentation is of Industrial Pharmacy-II Unit-I (Topic - Pilot Plant Scale up Techniques). ppt is very useful for student of B.pharmacy
This document provides information about pharmaceutical pilot plants. It defines a pilot plant as the part of the pharmaceutical industry where a lab scale formula is transferred into a viable product. The objectives of a pilot plant are to produce stable dosage forms, review equipment, provide manufacturing guidelines, and identify critical process aspects. A pilot plant is used to scale up the manufacturing process from lab to production scale before committing funds to a full production plant. It allows examination of formulas, equipment, production rates, and identification of issues to resolve prior to full scale production.
The document discusses pilot plant scale-up techniques. A pilot plant allows examination of a product and process on an intermediate scale before committing to full-scale production. It is important for identifying critical process parameters, producing samples for evaluation, and providing data to determine feasibility of full-scale production. The document outlines general considerations for pilot plant setup and operation including personnel requirements, equipment needs, production rates, process evaluation, and GMP compliance.
This document outlines the process and considerations for pilot plant scale-up of pharmaceutical manufacturing. It defines a pilot plant as transforming a lab-scale formula into a viable product through developing a reliable manufacturing procedure. The objectives of a pilot plant are to produce stable dosage forms, review equipment, establish production guidelines and controls, evaluate and validate processes and equipment, and determine a master manufacturing formula. Key steps involve reviewing the formula, approving raw materials, selecting appropriate sized equipment, determining production rates, developing standard operating procedures, and conducting stability testing. Personnel with both scientific and engineering knowledge are needed, and facilities must allow for physical testing, equipment, raw materials storage, and record keeping. Adherence to good manufacturing practices is also important for a
PILOT PLANT SCALE- UP TECHNIQUE
Plant, Pilot Plant, Scale-up, Objective, Significance, Steps in scale up, General considerations, Master Manufacturing Procedures, GMP consideration.
This document discusses the space requirements and considerations for designing a pharmaceutical pilot plant facility. It outlines that the facility should have separate areas for administration, physical testing, standard equipment, and storage. The standard equipment area should contain portable intermediate and full-scale production equipment for evaluating scale-up effects. The document also discusses raw material approval and validation, master batch records, analytical method transfer, product stability testing, and GMP compliance considerations like equipment qualification and validation.
This document discusses the purpose and operation of a pilot plant in the pharmaceutical industry. It states that a pilot plant allows investigation of a product and process on an intermediate scale before large-scale production is committed to. This helps evaluate results from laboratory studies, produce small quantities of product for testing, and provide data to determine if full-scale production is viable. The document outlines considerations for personnel, space, equipment, raw materials, and production rates in setting up a pilot plant.
Introduction, Objective; Significance; General consideration; Pilot plant scale up technique for solid, liquid and semi solids; SUPAC Guidelies; Introduction to platform technology
This document discusses techniques for scaling up pilot plant operations in the pharmaceutical industry. It begins with definitions of key terms and explains the significance of pilot plants in permitting examination of formulas at an intermediate scale. The document outlines general considerations for pilot plant operations, including personnel requirements, equipment used, production rates, and process evaluation. It also covers master manufacturing procedures, product stability testing, and GMP compliance. Advantages are given as personnel can observe scale up runs and quality materials can be accessed, while disadvantages include reduced interaction between formulators and production staff.
Pilot plant scale-up is a branch of the pharma companies in which a lab-scale formula is converted into a commercially viable product by creating a reliable manufacturing technique. The same techniques employed in dosage form Research and Development are adapted to multiple output volumes, frequently larger than those obtained during Research and Development. There is always a requirement for an intermediate batch scale describing techniques and imitating those in commercial manufacturing in any new or established pharmaceutical sector. This is accomplished by testing the formula’s ability to survive batch-scale and process changes.
1. The document discusses the objectives and rationale for pilot plant studies in pharmaceutical manufacturing, which include developing stable dosage forms, identifying critical process steps, and establishing a master formula.
2. It outlines the general considerations for pilot plant design such as personnel requirements, space needs, raw material validation, relevant equipment selection, and production rates.
3. Process evaluation and optimization is critical, which involves examining parameters like mixing times and temperatures, and ensuring the process consistently produces products meeting specifications.
The document discusses pilot plant scale up techniques for pharmaceutical manufacturing. It begins by defining key terms like pilot plant, scale-up, and objectives of pilot plant studies. It then describes the steps involved in pilot plant scale up for solid oral dosage forms including granulation, drying, milling, blending, compression, and coating processes. Specific considerations for scaling up each unit operation are discussed. The document also covers scale up of liquid oral dosage forms and the equipment used. Finally, it lists important documentation required for pilot plant scale up including standard operating procedures, batch records, specifications, and guidelines like SUPAC.
1. A pilot plant allows for transforming a lab scale formula into a viable product by developing reliable manufacturing procedures at an intermediate scale. This helps identify any issues before committing to full-scale production.
2. Key objectives of a pilot plant include evaluating results from laboratory studies, producing small quantities of product for testing, and determining parameters for full-scale production.
3. Important considerations for pilot plant development include the type and size of equipment needed, proper location, staffing requirements, and ensuring compliance with Good Manufacturing Practices.
This document discusses techniques for scaling up processes from a pilot plant to full production. It covers definitions of pilot plants, their significance in allowing examination of formulas and refinement of processes and equipment. General considerations for pilot plants include reporting structure, personnel requirements, space needs, and review of formulas and raw materials. Process evaluation and development of master manufacturing procedures are also covered. The document discusses various dosage forms including solids, liquids, parenterals, and semisolids, outlining equipment and parameters considered for scaling up each type of product. GMP considerations and advantages and disadvantages of pilot plants are also summarized.
The document discusses the design and operation of a pilot plant for tablet and capsule production. It provides details on:
1) The purpose of a pilot plant is to transform a lab-scale formula into a viable product by developing reliable manufacturing methods. It helps evaluate scale-up and technology transfer.
2) Key considerations for pilot plant design include simulating production equipment, identifying critical parameters, and collecting data to characterize unit operations while following cGMP.
3) The document outlines various unit operations like blending, granulation, drying, milling and compression and important aspects to consider when scaling them up.
industrial pharmacy chapter 1: pilot plant scale up techniques Kanchan Patil
The document discusses key considerations for scaling up processes from a pilot plant to full production. It covers major technical aspects like identifying critical components and process parameters. The objectives of pilot plant scale up are to avoid problems, prepare production guidelines, and validate the process and equipment. Scale up requires evaluating factors like material handling, chemical weighing, blending, granulation, drying, and ensuring compliance with cGMP guidelines. The reporting responsibilities, personnel requirements, facility requirements, training needs, and technology transfer are also addressed.
Similar to PILOT PLANT SCALE UP TECHNIQUES BY MOHAMMAD A. KHAN (20)
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
This presentation was provided by Steph Pollock of The American Psychological Association’s Journals Program, and Damita Snow, of The American Society of Civil Engineers (ASCE), for the initial session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session One: 'Setting Expectations: a DEIA Primer,' was held June 6, 2024.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar Kanvaria
How to Build a Module in Odoo 17 Using the Scaffold MethodCeline George
Odoo provides an option for creating a module by using a single line command. By using this command the user can make a whole structure of a module. It is very easy for a beginner to make a module. There is no need to make each file manually. This slide will show how to create a module using the scaffold method.
A workshop hosted by the South African Journal of Science aimed at postgraduate students and early career researchers with little or no experience in writing and publishing journal articles.
Executive Directors Chat Leveraging AI for Diversity, Equity, and InclusionTechSoup
Let’s explore the intersection of technology and equity in the final session of our DEI series. Discover how AI tools, like ChatGPT, can be used to support and enhance your nonprofit's DEI initiatives. Participants will gain insights into practical AI applications and get tips for leveraging technology to advance their DEI goals.
PILOT PLANT SCALE UP TECHNIQUES BY MOHAMMAD A. KHAN
1. PILOT PLANT SCALE UP
TECHNIQUES
Mohammad Ataulla Khan
B.PHARM 7th SEM
Regd. No. : 1803268048
Subject : Industrial Pharmacy II
Concern Teacher: Mr. Aswini Sethy
Jeypore College Pharmacy
3. What is pilot plant :
It is the part of the pharmaceutical industry where a lab
scale formula is transformed into a viable product by
developement of liable practical procedure of manufacturing.
R & D Production
Pilot Plant
Scale Up :
The art of designing of prototype using the data
obtained from the pilot plant model.
Introduction:
4. To find mistakes on small scale and make profit on large
scale.
To produce physically and chemically stable therapeutic
dosage form.
Review of the processing equipment.
Guidelines for production and process control.
evaluation and validation.
To identify the critical features of the process.
To provide master manufacturing formula.
OBJECTIVES :
5. Close examination of formula.
Review of equipment - most compatible with the
formulation & economical, simple & reliable in producing
product.
The specification of the raw material.
Give rough idea about physical space required and of
related functions.
Appropriate records & reports to support GMP.
IMPORTANCE :
6. 1. Reporting responsibility :
R &D group with The formulator who developed the
separate staffing . product can take into the production and
can provide support even after transition
into production has been completed.
GENERAL CONSIDERATION :
7. 2. Space requirements :
Administration Physical testing Standard equipment storage area
and information area floor space
processing
• Administration and information process:
Adequate office and desk space should be provided for
both scientist and technicians.
The space should be adjacent to the working area.
8. • Physical testing area:
This area should provide permanent bench top space
for routinely used physical- testing equipment.
• Standard pilot-plant equipment floor space:
Discreet pilot plant space, where the equipment needed for
manufacturing all types of dosage form is located. Intermediate – sized
and full scale production equipment is essential in evaluating the effects
of scale-up of research formulations and processes. Equipments used
should be made portable so that, after use it can be stored in the small
store room. Space for cleaning of the equipment should be also
provided.
• Storage Area :
Different areas should provided for the storage of the
in-process materials, finished bulk products from the pilot-
plant & materials from the experimental scale-up batches
made in the production. Storage area for the packing
material should also be provided.
9. • A thorough review of the each aspect of
formulation is important.
• The purpose of each ingredient and it’s contribution
to the final product manufactured on the small-scale
laboratory equipment should be understood.
• Then the effect of scale-up using equipment that
may subject the product of different types and
degrees can more readily recognized.
3. Review of the formula :
10. 4. Raw Materials :-
• One purpose/responsibility of the pilot-plant is the
approval & validation of the active ingredient & excipients
raw materials.
• Raw materials used in the small scale production
cannot necessarily be the representative for the large
scale production.
5. Equipments:
• The most economical and the simplest & efficient
equipments are used.
• The size of the equipment should be such that the
experimental trials run should be relevant to the
production sized batches.
• If equipment is too big then the wastage of the expensive
active ingredients.
11. 6. Production Rates:-
The immediate as well as the future market
trends/requirements are considered while determining
the production rates.
7. Process Evaluation:
PARAMETERS
Heating &
cooling rates
Rate of addition of
granulating
agents, solvents
etc.
Mixing time &
speed
Order of
mixing of
components
Drying temp.
& drying time
Screen size
Filters size